Full-Time

Associate Production Planner

Posted on 9/10/2026

Revvity

Revvity

1,001-5,000 employees

Translational multi-omics and diagnostics provider

No salary listed

Hopkinton, MA, USA

In Person

Bachelor's, Associate's

Category
Operations & Logistics (1)
Required Skills
ERP
SAP Products
Data Analysis
Excel/Numbers/Sheets

Get referred to Revvity

See people who can refer or advise you

Requirements
  • A bachelor's degree and 0–2+ years of production planning experience using an enterprise resource planning system, or an associate degree and 2+ years of such experience, or a high school diploma or GED and 4+ years of such experience.
  • Experience using an enterprise resource planning system for production planning.
  • SAP experience is preferred.
  • Advanced Microsoft Excel skills, including PivotTables, VLOOKUP/XLOOKUP, and data analysis, are preferred.
  • Planning and scheduling knowledge and background are preferred.
  • Ability to manage multiple priorities effectively.
  • Flexibility and willingness to adapt to change.
Responsibilities
  • Create production or work orders to plan, schedule, and maintain plant production control to meet internal and external customer orders by the targeted site or system commit date.
  • Monitor and maintain planning parameters, master data, lead times, safety stock, reorder points, and lot-sizing settings in SAP.
  • Schedule production lines for different instrument product groups and associated assemblies, factoring in production routing time and material lead time.
  • Convert planned orders into production orders and coordinate execution with manufacturing teams.
  • Work with Production to set cell inventory levels and maintain safety stock for production usage.
  • Work with Purchasing to check material availability and run material simulations to identify risks to targeted build plans.
  • Work with Logistics to support timely replenishment of parts for production and shipping of finished goods.
  • Work with Engineering on technical issues and support Engineering Change changeovers.
  • Work with Service to ensure timely availability of materials for field service.
  • Attend work-cell meetings with production lines and support departments to review SAP data and align production and material-flow processes with SAP processes.
  • Attend weekly Quality meetings to discuss customer returns and quality constraints affecting production, and support processing rejects and returns in the system.
  • Attend monthly Business Unit meetings to review SiOP and future sales forecasts, agree on build plans, maintain the production plan in SAP, and maintain build plan sheets.
  • Perform regular system checks for consumption and backflushing processes, correct issues, pre-flush and backflush production orders, post goods receipts into defined storage locations, and clear exceptions and anomalies.
  • Participate in the annual stock count with Finance, including second counts and system investigation work to maintain stock integrity and accuracy.
  • Support site new product introductions, end-of-life activities, and product transfers in planning-related areas.
  • Support Planning Department key performance indicators and benchmark practices in planning, order maintenance, output, inventory control, quality, and customer satisfaction.
  • Work with departments to enforce Lean principles and drive continuous improvements in planning practices and performance.
Desired Qualifications
  • Strong analytical and problem-solving capabilities.
  • Good communication skills.
  • Good team player.

Revvity provides health science solutions that span the full journey from discovery to development and from diagnosis to cure. It offers translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics, all delivered as integrated workflows and expert services. The company differentiates itself with an end-to-end platform that combines omics, imaging, biomarkers, and data analytics with specialized support to speed development. Its goal is to turn previously impossible healthcare outcomes into achievable results, advancing discovery, development, diagnosis and patient care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2023

Get referred to Revvity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $730 million; adjusted margins hit 28.9%.
  • Revvity raised 2026 guidance to $2.83-$2.86 billion revenue and $5.30-$5.40 EPS.
  • SuperFlex launched August 10, 2026, targeting underserved lower-volume prenatal labs immediately.

What critics are saying

  • Revvity is closing Boston and Lawrence sites, with 282 Massachusetts WARN layoffs through 2026.
  • China immunodiagnostics, about 6% of 2025 revenue, exits by end-2027.
  • T-SPOT A201 depends on 2027 regulatory approval; failure weakens infectious-disease growth.

What makes Revvity unique

  • Revvity bundles SuperFlex, T-SPOT A201, and LifeCycle into decentralized workflows.
  • Revvity's 2026 portfolio spans prenatal screening, TB automation, and biopharma informatics.
  • ACD/Labs acquisition and Signals software deepen Revvity's discovery-to-diagnosis platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Aug 13th, 2026
Revvity launches SuperFlex prenatal screening system for smaller labs

Revvity has launched SuperFlex, a compact prenatal screening system designed for small and mid-sized laboratories. The CE-IVDR-certified automated immunoassay instrument will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. The benchtop immunoanalyser processes up to 60 tests per hour and delivers initial results in 14 minutes. It supports preeclampsia screening and prenatal testing using chemiluminescence immunoassay technology with 24 sample positions. SuperFlex aims to address financial and operational barriers in lower-volume testing environments by offering lower instrument costs, reduced maintenance expenses, and no reagent wastage. The platform integrates with Revvity's LifeCycle software. Revvity shares gained 1.6% following the announcement and have risen 21.8% year-to-date. The company has a market capitalisation of $12.91 billion.

Associated Press
Aug 10th, 2026
Revvity launches SuperFlex system to expand preeclampsia screening access in lower-volume labs

Revvity has launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system tests for preeclampsia, which affects 2% to 8% of pregnancies globally. The platform features affordable instrument costs with annual maintenance, no reagent wastage at low volumes, and delivers results in as little as 14 minutes per test. It includes a test menu for first- and second-trimester biochemical prenatal screening. The system will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people.

Yahoo Finance
Aug 10th, 2026
Upstart named buy amid 30.6% revenue growth forecast, Revvity and Northern Trust flagged as risky

Upstart, an AI-powered lending platform, stands out as a buy opportunity among profitable stocks, according to StockStory's analysis. The company uses machine learning to assess borrower risk for various loan types. Upstart's loan originations surged 54.3% over the past year, enabling increased fee collection and expansion into new markets like credit cards. The company's revenue is expected to grow 30.6% over the next 12 months, with free cash flow anticipated to turn positive next year. Meanwhile, StockStory advises caution on Revvity and Northern Trust. Revvity's sales declined 10.6% annually over five years, whilst Northern Trust's 6.9% annual revenue growth lagged behind financial peers. Both companies face headwinds despite maintaining profitability, with earnings pressures and market share concerns affecting their outlooks.

Yahoo Finance
Aug 10th, 2026
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing Business Wire

Yahoo Finance
Aug 4th, 2026
Revvity reports $730M Q2 revenue, 4% growth, and raises full-year guidance

Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.